Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone.
OBJECTIVE
To examine the prognostic significance of expression of glutathione s-transferase pi (GST-pi) and p53 in patients treated with radiation alone for locally advanced head and neck cancer [Radiation Therapy Oncology Group (RTOG), trial 9003] or radiation +/- concomitant chemotherapy as postoperative adjuvant therapy (RTOG trial 9501).


METHODS
Immunohistochemical staining for p53 and GST-pi was done on tissue samples from 393 patients in RTOG 9003 and 142 patients in RTOG 9501. Kaplan-Meier survival analyses were done.


RESULTS
Patients who had low expression of both markers had longer survival than patients who had high expression of both markers. In trial 9003, median survival was 2.4 years for patients with low expression of both markers versus 1.4 years for patients who had elevated expression of both markers (P = 0.07). These differences were highly significant in trial 9501 and were accounted for by the chemotherapy treated arm. In this group, patients with low expression of both markers had a median survival of 7.0 years compared with 1.4 years for patients with elevated expression of both markers (P = 0.006). In both trials, black patients had lower survival rates than did white patients and there was a trend toward higher expression of both markers in blacks compared with whites.


CONCLUSIONS
Given the poor outcome of chemoradiotherapy treatment patients with elevated expression of both p53 and GST-pi, these patients may not be appropriate candidates for chemoradiotherapy based on standard protocols. Some of the adverse outcome for black patients in both studies may be attributed to elevated expression of p53 and GST-pi.
Schumaker
Lisa
L
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, USA.
Nikitakis
Nikolaos
N
Goloubeva
Olga
O
Tan
Ming
M
Taylor
Rodney
R
Cullen
Kevin J
KJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D044383:Black People; D003131:Combined Modality Therapy; D005260:Female; D051549:Glutathione S-Transferase pi / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D044465:White People
D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53; D051549:Glutathione S-Transferase pi
Oncol Rep. 2003 Sep-Oct;10(5):1461-6
12883724
Clin Cancer Res. 2002 Nov;8(11):3445-53
12429633
Curr Opin Oncol. 2000 May;12(3):229-39
10841195
Community Dent Oral Epidemiol. 2007 Jun;35(3):233-40
17518970
Clin Cancer Res. 2005 Feb 1;11(3):1160-6
15709184
JAMA. 1994 Sep 28;272(12):947-54
8084062
Clin Cancer Res. 1999 Dec;5(12):4097-104
10632346
Oral Oncol. 2007 Feb;43(2):193-8
16854613
Cancer Res. 2003 Dec 1;63(23):8097-102
14678959
JAMA. 2002 Apr 24;287(16):2106-13
11966385
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16
10924966
Int J Cancer. 2005 Feb 20;113(5):789-97
15499618
Mod Pathol. 1998 Feb;11(2):155-68
9504686
Clin Cancer Res. 2004 May 1;10(9):3110-6
15131051
Cancer. 2001 Jan 1;91(1 Suppl):279-83
11148594
J Am Dent Assoc. 2006 Feb;137(2):203-12
16521387
N Engl J Med. 2007 Oct 25;357(17):1705-15
17960013
Clin Cancer Res. 1996 Nov;2(11):1859-65
9816141
Cancer Chemother Pharmacol. 2000;46(4):255-62
11052622
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):166-72
14734465
J Natl Cancer Inst. 1993 Jul 21;85(14):1129-37
8320742
N Engl J Med. 2004 May 6;350(19):1937-44
15128893
Head Neck. 2008 Mar;30(3):358-71
17972309
Head Neck. 2005 Nov;27(11):982-9
16136583